Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), proudly announces the next chapter of its 2024 BOTOX® Cosmetic grant program, focused on empowering women entrepreneurs. This phase introduces crowdfunding campaigns for each of the 20 grant recipients, providing the public…
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has released its interim financial results for the first half of 2024, along…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral medication, demonstrating a significant reduction in the transmission of influenza viruses. The study successfully met its primary…
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative, next-generation treatments, recently shared key clinical accomplishments and outlined its upcoming milestones. “We’re making significant progress in…
Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at the 2024 American Society for Surgery of the Hand (ASSH)…
Alzprotect, a French biopharmaceutical company, has successfully completed the open-label extension (OLE) phase following its Phase 2a clinical trial of AZP2006 (ezeprogind®), a treatment for Progressive Supranuclear Palsy (PSP). The results of this 6-month extension highlight the potential of AZP2006…
Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”). UAS has increased the maximum aggregate principal amount for the…
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, has announced its financial results for the first quarter of fiscal 2025, ending on July 31, 2024. All figures are reported in Canadian dollars (CAD) unless stated otherwise.…
Tempus AI, Inc. (NASDAQ: TEM), a leader in advancing precision medicine through AI technology, has announced that four of its abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona,…
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. This vaccine is designed to protect adults 18…
Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a U.S.-based biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT), and Orano Med, a French subsidiary of the Orano Group focused on lead-212 (212Pb) radioligand…
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that BOTOX® Cosmetic (onabotulinumtoxinA) is now available in China for the treatment of masseter muscle prominence (MMP). The masseter muscle, located in the lower face, is involved in chewing, and…
